Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma

Gloria S. Huang, Lydia G. Chiu, Juliana S. Gebb, Marc J. Gunter, Paniti Sukumvanich, Gary L. Goldberg, Mark H. Einstein

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Objective.: The purpose of this study was to determine the clinical utility of CA125 measurement in patients with uterine carcinosarcoma (CS). Methods.: Ninety-five consecutive patients treated for CS at a single institution were identified. All 54 patients who underwent preoperative CA125 measurement were included in the study. Data were abstracted from the medical records. Tests of association between preoperative CA125 and previously identified clinicopathologic prognostic factors were performed using Fisher's exact test and Pearson chi-square test. To evaluate the relationship of CA125 elevation and survival, a Cox proportional hazard model was used for multivariate analysis, incorporating all of the prognostic factors identified by univariate analysis. Results.: Preoperative CA125 was significantly associated with the presence of extrauterine disease (P < 0.001), deep myometrial invasion (P < 0.001), and serous histology of the epithelial component (P = 0.005). Using univariate survival analysis, stage (HR = 1.808, P = 0.004), postoperative CA125 level (HR = 9.855, P < 0.001), and estrogen receptor positivity (HR = 0.314, P = 0.029) were significantly associated with survival. In the multivariate model, only postoperative CA125 level remained significantly associated with poor survival (HR = 5.725, P = 0.009). Conclusion.: Preoperative CA125 elevation is a marker of extrauterine disease and deep myometrial invasion in patients with uterine CS. Postoperative CA125 elevation is an independent prognostic factor for poor survival. These findings indicate that CA125 may be a clinically useful serum marker in the management of patients with CS.

Original languageEnglish (US)
Pages (from-to)513-517
Number of pages5
JournalGynecologic Oncology
Volume107
Issue number3
DOIs
StatePublished - Dec 1 2007

    Fingerprint

Keywords

  • CA125
  • Carcinosarcoma
  • Serum biomaker
  • Uterine neoplasm

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Huang, G. S., Chiu, L. G., Gebb, J. S., Gunter, M. J., Sukumvanich, P., Goldberg, G. L., & Einstein, M. H. (2007). Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecologic Oncology, 107(3), 513-517. https://doi.org/10.1016/j.ygyno.2007.08.060